Biological role of survivin;Biologiczna rola surwiwiny

Wspolczesna Onkologia

Volumn 12, Issue 10, 2008, Pages 437-440

  Karczmarek Borowska, Bozenna ^a   Zmorzyński, Szymon ^b   Filip, Agata ^b  

^a UNIVERSITY OF RZESZÓW   (Poland)

^b Uniwersytet Medyczny   (Poland)

Author keywords

Apoptosis; Cancerogenesis; Cell cycle; Survivin

Indexed keywords

CASPASE; MESSENGER RNA; SURVIVIN;

APOPTOSIS; ARTICLE; CANCER CELL; CARCINOGENESIS; CHEMOPROPHYLAXIS; HUMAN; MITOSIS; OSTEOSARCOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION;

EID: 67149119058     PISSN: 14282526     EISSN: 14282526     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Kren L, Brazdil J, Hermanova M, Goncharuk VN, Kallakury BV, Kaur P, Ross JS. Prognostic significance of anti-apoptosis proteins survivin and bcl-2 in non-small cell lung carcinomas: a clinicopathologic study of 102 cases. Appl Immunohistochem Mol Morphol 2004; 12: 44-9.
2. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
3. Vischioni B, van der Valk P, Span SW, Kruyt FA, Rodriguez JA, Giaccone G. Nuclear localization of survivin is a positive prognostic factor for survival advanced non-small-cell lung cancer. Ann Oncol 2004; 15: 1654-60.
4. Chiou SK, Jones MK, Tarnawski AS. Survivin - an anti-apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 2003; 9: 125-9.
5. Caldas H, Honsey LE, Altura RA. Survivin 2alpha: a novel Survivin splice variant expressed in human malignancies. Mol Cancer 2005; 4: 11.
6. Mahotka C, Wenzel M, Springer E, Gabbert HE, Gerharz CD. Survivin-deltaEx3 and survivin-2B: two novel splice variants of the apoptosis inhibitor survivin with different antiapoptotic properties. Cancer Res 1999; 59: 6097-102.
7. Li F. Role of survivin and its splice variants in tumorigenesis. Br J Cancer 2005; 92: 212-6.
8. Meng H, Lu CD, Sun YL, Dai DJ, Lee SW, Tanigawa N. Expression level of wild-type survivin in gastric cancer is an independent predictor of survival. World J Gastroenterol 2004; 10: 3245-50.
9. Mahotka C, Krieg T, Krieg A, Wenzel M, Suschek CV, Heydthausen M, Gabbert HE, Gerharz CD. Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas. Int J Cancer 2002; 100: 30-6.
10. Mahotka C, Liebmann J, Wenzel M, Suschek CV, Schmitt M, Gabbert HE, Gerharz CD. Differential subcellular localization of functionally divergent survivin splice variants. Cell Death Differ 2002; 9: 1334-42.
11. Okada H, Mak TW. Pathways of apoptotic and non-apoptotic death in tumour cells. Nat Rev Cancer 2004; 4: 592-603.
12. Shinohara ET, Gonzalez A, Massion PP, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected non-small cell lung carcinoma. Cancer 2005; 103: 1685-92.
13. Li F, Ling X. Survivin study: an update of "what is the next wave"? J Cell Physiol 2006; 208: 476-86.
14. Vegran F, Boidot R, Oudin C, Riedinger JM, Lizard-Nacol S. Distinct expression of Survivin splice variants in breast carcinomas. Int J Oncol 2005; 27: 1151-7.
15. Li F. Survivin study: what is the next wave? J Cell Physiol 2003; 197: 8-29.
16. Honda R, Körner R, Nigg EA. Exploring the functional interactions between Aurora B, INCENP, and survivin in mitosis. Mol Biol Cell 2003; 14: 3325-41.
17. Wheatley SP, Henzing AJ, Dodson H, Khaled W, Earnshaw WC. Aurora-B phosphorylation in vitro identifies a residue of survivin that is essential for its localization and binding to inner centromere protein (INCENP) in vivo. J Biol Chem 2004; 279: 5655-60.
18. Vong QP, Cao K, Li HY, Iglesias PA, Zheng Y. Chromosome alignment and segregation regulated by ubiquitination of survivin. Science 2005; 310: 1499-504.
19. Sampath SC, Ohi R, Leismann O, Salic A, Pozniakovski A, Funabiki H. The chromosomal passenger complex is required for chromatin-induced microtubule stabilization and spindle assembly. Cell 2004; 118: 187-202.
20. Vader G, Kauw JJ, Medema RH, Lens SM. Survivin mediates targeting of the chromosomal passenger complex to the centromere and midbody. EMBO Rep 2005; 7: 85-92.
21. Earnshaw WC. Keeping survivin nimble at centromeres in mitosis. Science 2005; 310: 1443-4.
22. Noton EA, Colnaghi R, Tate S, Starck C, Carvalho A, Ko Ferrigno P, Wheatley SP. Molecular analysis of survivin isoforms: Evidence that alternatively spliced variants do not play a role in mitosis. J Biol Chem 2006; 281: 1286-95.
23. Ling X, Yang J, Tan D, et al. Differential expression of survivin-2B and survivin-DeltaEx3 is inversely associated with disease relapse and patient survival in non-small-cell lung cancer (NSCLC). Lung Cancer 2005; 49: 353-61.
24. Islam A, Kageyama H, Hashizume K, Kaneko Y, Nakagawara A. Role of survivin, whose gene is mapped to 17q25, in human neuroblastoma and identification of a novel dominant-negative isoform, survivin-beta/2B. Med Pediatr Oncol 2000; 35: 550-3.
25. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 14: 1117-27.
26. Fennell DA. Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploration. Clin Cancer Res 2005; 11: 2097-105.
27. Endoh T, Tsuji N, Asanuma K, Yagihashi A, Watanabe N. Survivin enhances telomerase activity via up-regulation of specificity protein 1- and c-Myc-mediated human telomerase reverse transcriptase gene transcription. Exp Cell Res 2005; 305: 300-11.
28. Dabrowski A, Filip A, Zgodziñski W, Dabrowska M, Polañska D, Wójcik M, Zinkiewicz K, Wallner G. Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol 2004; 42: 179-2.
29. Nakanishi K, Kawai T, Kumaki F, Hiroi S, Mukai M, Ikeda E. Survivin expression in atypical adenomatous hyperplasia of the lung. Am J Clin Pathol 2003; 120: 712-9.
30. Trieb K, Lehner R, Stulnig T, Sulzbacher I, Shroyer KR. Survivin expression in human osteosarcoma is a marker for survival. Eur J Surg Oncol 2003; 29: 379-82.
31. Falleni M, Pellegrini C, Marchetti A, et al. Survivin gene expression in early-stage non-small cell lung cancer. J Pathol 2003; 200: 620-6.
32. Karczmarek-Borowska B. Ekspresja wybranych białek i genów antyapoptycznych oraz genu supresorowego P53 w niedrobnokomórkowym raku płuca. Akademia Medyczna, Lublin 2006; 1-178.
33. Oshita F, Ito H, Ikehara M, et al Prognostic impact of survivin, cyclin D1, integrin beta1, and VEGF in patients with small adenocarcinoma of stage I lung cancer. Am J Clin Oncol 2004; 27: 425-8.
34. Ikehara M, Oshita F, Kameda Y, et al. Expression of survivin correlated with vessel invasion is a marker of poor prognosis in small adenocarcinoma of the lung. Oncol Rep 2002; 9: 835-8.
35. Grabowski P, Kühnel T, Mühr-Wilkenshoff F, Heine B, Stein H, Höpfner M, Germer CT, Scherübl H. Prognostic value of nuclear survivin expression in oesophageal squamous cell carcinoma. Br J Cancer 2003; 88: 115-9.
36. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc 2001; 34: 207-12.
37. Aziz MH, Afaq F, Ahmad N. Prevention of ultraviolet-B radiation damage by resveratrol in mouse skin is mediated via modulation in survivin. Photochem Photobiol 2005; 81: 25-31.
38. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004; 64: 337-46.
39. Dohi T, Beltrami E, Wall NR, Plescia J, Altieri DC. Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis. J Clin Invest 2004; 114: 1117-27.
40. Kanwar JR, Shen WP, Kanwar RK, Berg RW, Krissansen GW. Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy. J Natl Cancer Inst 2001; 93: 1541-52.